<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209364</url>
  </required_header>
  <id_info>
    <org_study_id>35GA0608</org_study_id>
    <nct_id>NCT01209364</nct_id>
  </id_info>
  <brief_title>Durolane Versus Methylprednisolone in Knee Osteoarthritis</brief_title>
  <official_title>Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether Durolane is non-inferior to methylprednisolone,
      as assessed by level of pain, when each are given as single intra-articular injections for
      the relief of pain, in the treatment of symptomatic osteoarthritis of the knee at 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain level and responder rate</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC stiffness score</measure>
    <time_frame>26 weeks blinded phase + 26 weeks OLE</time_frame>
    <description>Will be assessed at each clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC physical function</measure>
    <time_frame>26 weeks blinded phase + 26 weeks OLE</time_frame>
    <description>Will be assessed at each clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional assessment</measure>
    <time_frame>26 weeks blinded phase + 26 weeks OLE</time_frame>
    <description>Will be assessed at each clinic visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment (Adverse Events)</measure>
    <time_frame>26 weeks blinded phase + 26 weeks OLE</time_frame>
    <description>Will be assessed at each clinic visit using standard questions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">442</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Durolane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraarticular hyaluronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraarticular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durolane is a device, methylprednisolone in a drug</intervention_name>
    <description>single intraarticular injection</description>
    <arm_group_label>Durolane</arm_group_label>
    <arm_group_label>methylprednisolone</arm_group_label>
    <other_name>Durolane and Depo-Medrol are the brand names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject (female or male) 35-80 years of age

          -  Unilateral knee pain

          -  Radiographic evidence of OA

          -  WOMAC pain score of 7-17

          -  Subject normally active

          -  Subject has attempted but not responded adequately to previous non-pharmacological
             therapy(ies);

          -  Subject cooperative and able to communicate effectively with the investigators;

          -  Body mass index ≤ 40 kg/m2;

          -  Signed informed consent obtained.

        Exclusion Criteria:

          -  Knee effusion

          -  Contralateral knee OA

          -  Clinically significant joint pain from joints other than the knee

          -  Previous intra-articular steroid injection into the study knee within the last 3
             months;

          -  Previous intra-articular HA injection into the study knee within the last 9 months;

          -  Previous allergic type reaction to a HA product, a steroid, or lidocaine/related
             anesthetics;

          -  Treatment with analgesics other than paracetamol (acetaminophen) (including topical
             agents for the knee) within 5 half lives of the drug prior to the baseline visit;

          -  Use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3
             months;

          -  Treatment with glucosamine/chondroitin sulfate initiated within the past 3 months

          -  Change in physical therapy for the knee within the last three months

          -  Arthroscopy or other surgical procedure in the study knee within the past 12 months;

          -  Any planned arthroscopy or other surgical procedure during the study period;

          -  Previous history or presence of active septic arthritis

          -  Active skin disease or infection in the area of the injection site;

          -  Systemic active inflammatory condition or infection

          -  Bleeding diathesis or use of anticoagulants

          -  Current uncontrolled diabetes mellitus;

          -  Any medical condition that in the opinion of the investigator makes the subject
             unsuitable for inclusion

          -  Pregnant or breastfeeding woman or woman of childbearing potential not practicing
             adequate contraception;

          -  Involvement in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alberta Bone &amp; Joint Health Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2P 3C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St John´s</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic &amp; Sport Medicine Institute of Nova Scotia</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Wilson</name>
      <address>
        <city>Lunenburg</city>
        <state>Nova Scotia</state>
        <zip>B0J2C0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre-New Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Ontario</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlton Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Research Inc.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fowler Kennedy Sport Medicine Clinic</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Program Research Group</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Dobson</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 6X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sport C.A.R.E. Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Rhumatologie St-Louis</name>
      <address>
        <city>Saint-Foy</city>
        <state>Quebec</state>
        <zip>G1W4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Osteoporosis Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkargruppen Kristinelund</name>
      <address>
        <city>Göteborg</city>
        <zip>411 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopediska huset</name>
      <address>
        <city>Johanneshov</city>
        <zip>121 77</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Ellenbogen</name>
      <address>
        <city>Malmö</city>
        <zip>211 36</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopediska huset</name>
      <address>
        <city>Stockholm</city>
        <zip>11360</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital - Department of Rheumatology</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University Clinical Research FacilityRoyal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Jones and Agnes Hunt Orthopaedic &amp; District Hospital - Institute of Orthopaedics</name>
      <address>
        <city>Oswestry</city>
        <zip>SY10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital - MRC Epidemiology Resource Center</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>November 6, 2012</last_update_submitted>
  <last_update_submitted_qc>November 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>comparative</keyword>
  <keyword>randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>non-inferior</keyword>
  <keyword>knee OA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

